Humanigen rises on deal to sell COVID drug in UK post authorization

Humanigen

16/06/2022 12:59

** Shares of drug developer Humanigen  HGEN.O  rise 3.9% to
$2.36 premarket
    ** Co enters into an agreement with PCI Pharma Services for
its experimental COVID-19 therapy lenzilumab (https://refini.tv/3tDNc79)
    ** PCI to purchase lenzilumab for resale and distribution in
the United Kingdom, if the drug is authorized in the country for
use in patients hospitalized with COVID-19
    ** HGEN is developing lenzilumab as a treatment for severe
immune reaction in hospitalized COVID-19 patients
    ** Stock down ~39% this year, as of last close
    

 (Reporting by Mrinalika Roy in Bengaluru)
 ((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 8325;))